Abdom Radiol (NY)

1. YANG B, Yang R, Zhang W, Ren X, et al
   Multi-DECT image-based intra- and peritumoral interpretable radiomics and artificial intelligence models for preoperative prediction of pathological grading of non-muscle-invasive bladder cancer.
   Abdom Radiol (NY). 2026 Jul 20. doi: 10.1007/s00261-026-05679.
   

   >> Share

   
   

   
   Aktuelle Urol

2. SCHNABEL MJ, Grimm MO, Goebell PJ, Hellmis E, et al
   [Perioperative Treatment with Durvalumab in Combination with Neoadjuvant Chemotherapy in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer].
   Aktuelle Urol. 2026 Jul 24. doi: 10.1055/a-2883-3946.
   

   >> Share

   
   

   
   Anal Bioanal Chem

3. FROLOVA A, Vokuev M, Ikhalainen Y, Prosuntsova D, et al
   A systematic DoE approach for optimizing urinary LC-HRMS metabolomics: enhancing reliability in bladder cancer profiling.
   Anal Bioanal Chem. 2026 Jul 24. doi: 10.1007/s00216-026-06678.
   

   >> Share

   
   

   
   Beijing Da Xue Xue Bao Yi Xue Ban

4. WANG Y, Song H, DU Y, Xu T, et al
   [CRISPR-Cas9 activation screening identifies candidate chemokine regulators of ter-tiary lymphoid structure formation in bladder cancer].
   Beijing Da Xue Xue Bao Yi Xue Ban. 2026;58:707-715.
   

   >> Share

   
   
5. DONG L, Peng Y, Song Y, Li X, et al
   [Development of a 36-gene signature for predicting recurrence in non-muscle-invasive bladder cancer and validation in a Chinese cohort].
   Beijing Da Xue Xue Bao Yi Xue Ban. 2026;58:794-802.
   

   >> Share

   
   
6. JI J, Lai C, Wang F, Hu H, et al
   [Impact of coexistent low-grade components on the prognosis of high-grade non-muscle invasive bladder cancer].
   Beijing Da Xue Xue Bao Yi Xue Ban. 2026;58:803-807.
   

   >> Share

   
   
7. ZHENG G, Peng Y, DU Y, Xu T, et al
   [Expression characteristics and clinical significance of ERBB2 in bladder urothelial carcinoma based on the TCGA database].
   Beijing Da Xue Xue Bao Yi Xue Ban. 2026;58:818-826.
   

   >> Share

   
   

   
   BMC Cancer

8. KURAL S, Kumar L, Pathak AK, Singh S, et al
   Non-invasive diagnostic evaluation of urinary exosomal let-7c cluster expression in bladder cancer using machine learning approaches.
   BMC Cancer. 2026 Jul 21. doi: 10.1186/s12885-026-16217.
   

   >> Share

   
   

   
   Cancer Immunol Immunother

9. AMRANE K, Campedel L, Moinard-Butot F, Gout M, et al
   Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study.
   Cancer Immunol Immunother. 2026;75:191.
   

   >> Share

   
   

   
   Cell Signal

10. HUI K, Wu S, Yue Y, Gu Y, et al
    Corrigendum to "RASAL2 inhibits tumor angiogenesis via p-AKT/ETS1 signaling in bladder cancer" [Cellular Signaling, 48 (2018) 38-44].
    Cell Signal. 2026 Jul 20:112730. doi: 10.1016/j.cellsig.2026.112730.
    

    >> Share

    
    

    
    Clin Transl Oncol

11. PAN M, Tao T, Peng J, Zhang Y, et al
    Prognostic value of platelet-to-lymphocyte ratio in bladder cancer: a systematic review and meta-analysis.
    Clin Transl Oncol. 2026 Jul 22. doi: 10.1007/s12094-026-04515.
    

    >> Share

    
    

    
    Comb Chem High Throughput Screen

12. SUN L, Yuan L
    Natural Biopeptide Hirudin Regulates Value-Added Metastasis of Bladder Cancer Cells by Activating PID1 Expression.
    Comb Chem High Throughput Screen. 2026.
    

    >> Share

    
    

    
    Cureus

13. NIKNAFS AM, Damron LF, Baclig NV, Iliopoulos M, et al
    Threading the Needle in Bladder Cancer: A Narrative Review of the Emerging Role of Integrative Oncology in Treatment-Related Adverse Events in the Era of Immunotherapy and Antibody-Drug Conjugates.
    Cureus. 2026;18:e111294.
    

    >> Share

    
    

    
    Cutis

14. MOECKEL C, Ferguson S
    Pembrolizumab-Induced Bullous Pemphigoid: Navigating Diagnostic Challenges and Treatment Resistance.
    Cutis. 2026;117:E14-E18.
    

    >> Share

    
    

    
    ESMO Open

15. POWLES T, Madjar K, Balas BI, Carter C, et al
    Higher rates of immune-related adverse events in circulating tumor DNA (ctDNA)-negative patients following adjuvant checkpoint inhibitor therapy.
    ESMO Open. 2026;11:107701.
    

    >> Share

    
    
16. ARAGON-CHING JB, Gupta S, Grivas P, Park SH, et al
    Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus.
    ESMO Open. 2026;11:107776.
    

    >> Share

    
    
17. MAIORANO BA, Maruzzo M, Slusarczyk A, Subiela JD, et al
    Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials.
    ESMO Open. 2026;11:108329.
    

    >> Share

    
    

    
    Eur J Oncol Nurs

18. ZHANG J, Li P, Liu L, Pan Z, et al
    Supportive-care burden among bladder cancer survivors in the United States: a nationally representative NHIS study.
    Eur J Oncol Nurs. 2026;84:103285.
    

    >> Share

    
    

    
    Eur Urol

19. DI BELLO F, Gallioli A, Breda A, Palou J, et al
    Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Uro
    Eur Urol. 2026 Jul 23:S0302-2838(26)02275-X. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
20. LAZZERI M, Hurle R, Lughezzani G, Buffi NM, et al
    Re: Comprehensive Genome-wide Association Study Into Multiple Recurrence and Progression Risk in Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2026 Jul 22:S0302-2838(26)02266-9. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    

    
    Eur Urol Focus

21. LEE DJ, Williams C, Soefje S, Flynn D, et al
    BCG at Home: A First-in-kind Trial of Home-based Intravesical Bacillus Calmette-Guerin Delivery for High-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2026 Jul 22:S2405-4569(26)00116.
    

    >> Share

    
    

    
    Front Immunol

22. DONG Y, Su Y
    Perspective on the integration of radiomics and spatial omics in the analysis of the tumor microenvironment of bladder cancer and prospects for precision diagnosis and treatment.
    Front Immunol. 2026;17:1821743.
    

    >> Share

    
    
23. QIN J, Zhou H, Li X, Yin H, et al
    Efficacy and safety of combining radiotherapy with first-line chemotherapy and immunotherapy for local advanced/metastatic urothelial cancer: a propensity score matching analysis.
    Front Immunol. 2026;17:1786952.
    

    >> Share

    
    

    
    Front Oncol

24. GUO M, Zhou Y, Lin X, Xu Z, et al
    The prognostic impact of squamous differentiation in bladder cancer after radical cystectomy: a propensity score-matched comparative analysis of pure urothelial carcinoma, urothelial carcinoma with squamous differentiation, and squamous cell carcinoma
    Front Oncol. 2026;16:1890852.
    

    >> Share

    
    
25. ALHUBAISHY B, Beshawri I, Abulreish I, Alnajar O, et al
    Sequential gemcitabine-docetaxel in BCG-naive and BCG-failure non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Front Oncol. 2026;16:1859461.
    

    >> Share

    
    
26. FERREIRA VG, Ehlert ME, Pacheco BS, Souza FSS, et al
    Preclinical translational screening of palladium(II)-porphyrin photosensitizers across human and Oncopig bladder cancer cell lines.
    Front Oncol. 2026;16:1882402.
    

    >> Share

    
    

    
    Funct Integr Genomics

27. YANG J, Li X, Wang L, Wan S, et al
    Single-cell and spatial transcriptomics identify CAPG as a key driver of cisplatin resistance in bladder cancer.
    Funct Integr Genomics. 2026;26:197.
    

    >> Share

    
    

    
    Genes Dis

28. MENG XY, Shi MJ, Li S, Liu M, et al
    Tobacco's dual genomic footprints in bladder cancer revealed by multi-omics analysis: An SBS4-like LumU-enriched signature and smoking-driven HRD-related genomic instability.
    Genes Dis. 2025;13:102001.
    

    >> Share

    
    

    
    Histol Histopathol

29. SAGLICAN Y, Unlu Y, Behzatoglu K
    Approach and nomenclature problems of extracutaneous basaloid neoplasias of visceral organs with three cases of basaloid carcinoma described for the first time in the urinary bladder.
    Histol Histopathol. 2026;41:1377-1385.
    

    >> Share

    
    

    
    Int Braz J Urol

30. FAVORITO LA
    Editorial Comment: Multiparametric Magnetic Resonance Imaging and Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnosis and Staging: A Guide for Clinicians from the American College of Radiology VI-RADS Steering Committee.
    Int Braz J Urol. 2026;52:e20269915.
    

    >> Share

    
    

    
    Int Cancer Conf J

31. YASUDA K, Tsujino M, Yamasaki H, Kurahashi Y, et al
    Rapidly progressive synchronous multifocal gastrointestinal stenoses in bladder cancer: diagnostic challenges and clinical implications.
    Int Cancer Conf J. 2026;15:342-348.
    

    >> Share

    
    

    
    Int J Biol Macromol

32. QIN J, Li Z, Su L, Wen X, et al
    Retraction notice to "Expression of transferrin receptor/TFRC protein in bladder cancer cell T24 and its role in inducing iron death in bladder cancer" [Int. J. Biol. Macromol. 274 (2024) 133323].
    Int J Biol Macromol. 2026 Jul 22:153488. doi: 10.1016/j.ijbiomac.2026.153488.
    

    >> Share

    
    
33. QIN J, Liao K, Huang L, Qiu R, et al
    Retraction notice to "Proteome-driven transcriptomic dissection of EMT networks in bladder cancer based on the VIM and CDH2 protein macromolecules influence: From molecular-protein subtyping to therapeutic target prioritization" [Int. J. Biol. Macromo
    Int J Biol Macromol. 2026 Jul 22:153573. doi: 10.1016/j.ijbiomac.2026.153573.
    

    >> Share

    
    

    
    Int J Clin Oncol

34. EIGNER E, Fazaa N, Nsair A, Atallah M, et al
    Risk of second primary malignancies after bladder cancer diagnosed at a young age: a SEER population-based analysis.
    Int J Clin Oncol. 2026 Jul 18. doi: 10.1007/s10147-026-03140.
    

    >> Share

    
    

    
    Int J Urol

35. TAOKA R, Hayakawa N, Kimura T, Kikuchi E, et al
    Consensus-Based Development of a Surgical Checklist for Transurethral Resection of Bladder Tumor: An Initiative of the Japanese Society of Urologic Oncology.
    Int J Urol. 2026;33:e70570.
    

    >> Share

    
    

    
    J Mol Diagn

36. JIN D, Wang H, Jiang C, Zhang F, et al
    Non-Invasive Detection of Bladder Cancer via Urinary DNA Mutation and Methylation Profiling Using Modified qPCR.
    J Mol Diagn. 2026 Jul 21:S1525-1578(26)00122.
    

    >> Share

    
    

    
    J Transl Med

37. CHEN X, Sakatani T, Tanaka S, Contreras-Sanz A, et al
    A bladder cancer-associated gene signature for exploratory qPCR-based survival stratification in NAC-Treated muscle-invasive bladder cancer.
    J Transl Med. 2026 Jul 21. doi: 10.1186/s12967-026-08681.
    

    >> Share

    
    

    
    JAMA Netw Open

38. HAMILTON-REEVES JM, Unger JM, Holzbeierlein JM, Lew DL, et al
    Immune-Enhancing Nutrition and Outcomes After Radical Cystectomy: A Randomized Clinical Trial.
    JAMA Netw Open. 2026;9:e2623622.
    

    >> Share

    
    

    
    Mol Biol Rep

39. SAJJADI S, Ramezani A, Alavimanesh S, Alipoor H, et al
    Integrative analysis identifies candidate biomarkers for bladder cancer: evidence from genomic and clinical validation.
    Mol Biol Rep. 2026;53:1205.
    

    >> Share

    
    

    
    N Engl J Med

40. GALSKY MD, Valderrama BP, Maruzzo M, Font A, et al
    Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.
    N Engl J Med. 2026;395:338-348.
    

    >> Share

    
    
41. SRIDHAR SS
    A New Standard in Muscle-Invasive Bladder Cancer - The End of the Cisplatin Era?
    N Engl J Med. 2026;395:402-404.
    

    >> Share

    
    

    
    Nat Commun

42. ZHOU D, Li Y, Yan Z, Huang J, et al
    Recurrence in the chemotherapy regimen of bladder carcinoma originates from quiescent epidermoid-like cells.
    Nat Commun. 2026;17:6902.
    

    >> Share

    
    

    
    Oncogene

43. SUN L, Yao Y, Gong S, Chen Z, et al
    YME1L1 degradation by TRIM21 inhibits bladder cancer proliferation, metastasis, and mitochondrial function.
    Oncogene. 2026 Jul 20. doi: 10.1038/s41388-026-03903.
    

    >> Share

    
    
44. CHENG Y, Chen Y, Wang J, Shu Z, et al
    DTX3 promotes anti-tumor immunity by inducing PD-L1 ubiquitination and is suppressed by p65/miR-222 in bladder cancer.
    Oncogene. 2026 Jul 24. doi: 10.1038/s41388-026-03915.
    

    >> Share

    
    

    
    Oncologist

45. NEOLA G, Flauto F, Caso C, Montuori G, et al
    The impact of relative dose intensity on pathological complete response in neoadjuvant chemotherapy of muscle-invasive urothelial cancer: a multicenter retrospective study.
    Oncologist. 2026;31:oyag256.
    

    >> Share

    
    

    
    Pharmacol Res

46. SHI T, Wen C, Wang Z, Jiao Y, et al
    Celastrol's covalent strike on HK2: Breaking a metabolic-epigenetic circuit to impede bladder cancer.
    Pharmacol Res. 2026;231:108349.
    

    >> Share

    
    

    
    Sci Rep

47. TIAN H, Han X
    Sexual experience of urostomy patients with bladder cancer: a qualitative explorative study.
    Sci Rep. 2026 Jul 19. doi: 10.1038/s41598-026-62589.
    

    >> Share

    
    

    
    Sci Transl Med

48. ROUANNE M, Chen N, Mariuzza DL, Yang Z, et al
    Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy in preclinical mouse models.
    Sci Transl Med. 2026;18:eadv7600.
    

    >> Share

    
    

    
    Transl Oncol

49. DONG C, Fang Z, Han Y, Yin Y, et al
    Centrosome-related gene SPHK1 drives bladder cancer progression and therapeutic vulnerability.
    Transl Oncol. 2026;71:102926.
    

    >> Share

    
    
50. LI Y, Wu L, Shi J, Li W, et al
    Single-cell and spatial transcriptomics reveal SUV39H1 as a master epigenetic driver of immunosuppressive niche and stemness in bladder cancer.
    Transl Oncol. 2026;71:102929.
    

    >> Share

    
    

    
    Tumori

51. OUYANG B, Wu Z, Li J, Zhu G, et al
    Preliminary study on intravesical instillation of IL-12 mRNA lipid nanoparticles for the treatment of bladder cancer.
    Tumori. 2026 Jul 23:3008916261463130. doi: 10.1177/03008916261463130.
    

    >> Share

    
    

    
    Urol Oncol

52. FILIANOTI A, Costantini M, Rosca V, Mastroianni R, et al
    Electronic nose-based urinary volatilome profiling accurately discriminates bladder cancer from healthy controls: A prospective diagnostic study.
    Urol Oncol. 2026 Jul 23:S1078-1439(26)00570.
    

    >> Share

    
    
53. NOWROOZI MR, Madani MH, Farzin A, Mazdak M, et al
    Deep learning approaches for predicting response to neoadjuvant chemotherapy in muscle invasive bladder cancer: A systematic review.
    Urol Oncol. 2026 Jul 21:S1078-1439(26)00567.
    

    >> Share

    
    
54. OBEROI JK, Ballas LK, Tyson M, Singh P, et al
    Ideal candidates for bladder preservation in muscle-invasive bladder cancer.
    Urol Oncol. 2026 Jul 24:S1078-1439(26)00584.
    

    >> Share

    
    

    
    Urology

55. SMITH AK
    Editorial Comment on "Extended versus Standard Lymph Node Dissection at the Time of Radical Cystectomy for Bladder Cancer".
    Urology. 2026 Jul 22:S0090-4295(26)00458-9. doi: 10.1016/j.urology.2026.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share